EU-PEARL brings together patients, clinicians, industry, researchers and authorities to create an open and trusted environment for knowledge sharing and science-driven debate on innovative clinical trials. Extensive cooperation amongst all stakeholders to improve health outcomes for patients is the driving force behind EU-PEARL.

We are building an innovative open access platform to offer companies and reference laboratories, the capabilities, knowhow, networks and services required for the development, testing, assessment, upscaling and market exploitation of nanotechnology-based Medical and Diagnosis Devices.

AdHopHTA performed a critical analysis of established hospital-based HTA initiatives in Europe. It provided an empirically founded set of principles for best practice in hospital-based HTA. The use of AdHopHTA’s products will promote cooperation and coordination between hospital-based HTA initiatives and facilitate their establishment in additional interested hospitals across Europe and the world.

The COVID-19 Pandemic has led to an unprecedented health and social crisis. We can all contribute to limiting Covid-19’s transmission and impact. BLUMORPHO, EuroScan international network and co-operation partners decided to offer their resources in the call #UnitedAgainstCovid19.

WHO is bringing the world’s scientists and global health professionals together to accelerate the research and development process, and develop new norms and standards to contain the spread of the coronavirus pandemic and help care for those affected.

Driven by the desire to further the advancement of Health Technology Assessment through collaboration, HTAi offers opportunities for its members to network.
HTAi is taken care of assessment, EuroScan is taken care of the needed evidence.Together means more. So we founded a common working group within TAi - DIsinvestment and early awareness - DEA